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Abstract 
Background: This study investigated whether single nucleotide polymorphisms (SNPs) in 
genes within the catechol estrogen metabolism pathway altered the risk of breast cancer 
alone or in combination, as well as whether menopausal hormone therapy (HT) modified 
the effect of these SNPs on breast cancer risk.   
Methods: In a population-based case-control study of breast cancer, 891 cases and 878 
controls were genotyped for six functional SNPs in the COMT, CYP1B1, GSTM1, 
GSTP1, and GSTT1 genes.   
Results: Women homozygous with the T allele in CYP1B1*2 (Ser119; rs1056827) were 
at 1.69 (95% confidence interval [CI]: 1.17-2.46) times the risk of women homozygous 
with the G allele; women homozygous with the G allele in GSTP1 (Val105; rs1695) were 
at 0.73 (95% CI: 0.54-0.99) times the risk of breast cancer compared to women 
homozygous with the A allele. No other SNPs tested were associated with breast cancer 
to any appreciable degree. Potential gene-gene and gene-HT interactions were 
investigated.     
Conclusion: With the exception of GSTP1 and possibly CYP1B1*2, our findings do not 
provide support for the role of genetic variation in the catechol estrogen metabolism 
pathway and breast cancer risk in post-menopausal women.   
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Introduction 
A vast accumulation of data has demonstrated that estrogen-related exposures 
play a role in breast cancer etiology (1,2).  Conceivably, this could be due in part to the 
mutagenic effects of estrogen’s intermediate metabolites within the catechol estrogen 
(CE) pathway.  There is evidence that genotoxicity may operate through the formation of 
reactive estrogen metabolites, namely catechol estrogen semiquinones and quinones 
which damage DNA via the formation of superoxide radicals and depurinating DNA 
adducts, although it is unclear what proportion of estradiol is converted into catechol 
estrogens (3-6).    
 It is plausible that estrogen’s genotoxic potential varies across individuals and 
may be influenced by genetic variation within the CE metabolism pathway.  Specifically, 
CYP1B1 plays a role in the conversion of 17β-estradiol (E2) into 4-OHE2 CE (3,5,7-9).  
Several SNPs within CYP1B1 have been shown to have functional effects on the catalytic 
properties of the CYP1B1 enzyme (9,10), and variant alleles of CYP1B1*2 (Ala119Ser) 
and CYP1B1*3 (Leu432Val) have been observed to be associated with breast cancer risk 
in some (11,12), but not all, previous studies (13-15).  Catechol-O-methyltransferase 
(COMT) is involved in methylating (and thereby inactivating) CEs (5,16). The COMT 
Met158 allele has been hypothesized to produce an enzyme with reduced functionality, 
although prior epidemiologic studies have not shown an association with breast cancer 
(9,14).  If CEs are not inactivated, they can be easily oxidized into CE semiquinones and 
then into CE quinones (5).  Members of the glutathione-S-transferase (GST) family are 
thought to play a role in the conjugation of CE quinones, with GSTP1 being the 
predominant GST enzyme found in the breast (16,17).  The GSTP1 Val105 allele has 
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been shown to confer different catalytic enzyme activity (16), however, the 
epidemiologic findings regarding breast cancer risk have been mixed (14,18-21). Null 
mutations have been characterized for both GSTM1 and GSTT1; for GSTM1, one pooled 
analysis reported a marginally significant, modestly increased risk of breast cancer 
associated with the null variant (14), while no increased risk was observed in a meta-
analysis (22); for the GSTT1 null variant, no pooled analyses have observed an 
association with breast cancer risk (14).  
The amount of catechol estrogens accumulating in the breast tissue from daily 
exposure to estrogen supplied by estrogen-progestin therapy (EPT) or estrogen-alone 
therapy (ET) may conceivably vary among post-menopausal women and may be affected 
by the variation in genes within the catechol estrogen metabolism pathway.  Several 
studies have investigated interactions between genes in this pathway, as well as gene-
EPT interactions, but no specific gene-gene combination has been observed to be 
associated with breast cancer in more than one study (19-21,23-25).  We investigated 
whether variation within five genes in the CE metabolism pathway was associated with 
an increased risk of breast cancer, and whether EPT and/or ET modified the effect of 
genotype on breast cancer risk.   
 
Materials and Methods 
Study Design and Data Collection  
The study participants were recruited for a population-based case-control study, 
the ‘Puget Sound Area Breast Cancer Evaluation (PACE) Study’ of invasive breast 
cancer among post-menopausal women of 65-79 years of age in western Washington 
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State.  The methods have been described in detail previously (26), and thus are 
summarized only briefly here.  Eligible case participants were: 1) women 65-79 years of 
age when diagnosed with primary, invasive breast cancer between April 1, 1997 and May 
31, 1999; 2) residents of the three county (King, Pierce, and Snohomish counties) Seattle-
Tacoma Metropolitan area at diagnosis; 3) women with no previous history of in situ or 
invasive breast cancer; and 4) women with the ability to communicate in English. All 
cases were ascertained through the Cancer Surveillance System (CSS), the population-
based tumor registry serving the Seattle-Puget Sound region of western Washington State 
and a participant in the Surveillance, Epidemiology, and End Results (SEER) Program of 
the National Cancer Institute.  The PACE study interviewed 975 cases (80.6 %) of those 
identified through the CSS. 
 Eligible control participants for the PACE Study were identified through the 
Center for Medicare and Medicaid Services’ (CMS) list of Social Security recipients 
from the general population of the same three county Metropolitan Seattle area from 
which the cases were drawn.  The CMS Social Security list includes all individuals age 
65 years and older residing in the United States who are eligible for Medicare benefits, 
including women whose income precludes eligibility to receive funds and women who 
elect not to receive cash benefits.  The controls for this study were randomly selected 
from the CMS rolls and were frequency matched to the expected distribution of cases by 
five-year age group.  Of the 1,365 controls selected, 1,007 women (73.8%) were 
interviewed. 
 Data collection for cases and controls was performed in an identical manner. For 
each participant, upon the attainment of informed consent, a structured, in-person 
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interview was conducted by a trained study interviewer on established and suspected 
breast cancer risk factors, including: demographic characteristics, reproductive history, 
menstrual history, hormonal contraception history, medical history, certain medications, 
weight and height history, lifestyle factors, family history of cancer, and hormonal 
therapy use.  The questions on hormonal therapy were extensive and solicited 
information on lifetime use, including drug name, start and stop dates of use, separate and 
combined uses of estrogen and progestin, strength, and monthly pattern of pill use.  All 
interview questions were limited to events occurring before each participant’s diagnosis 
date (reference date for controls).  Within the 5-year age groups on which controls were 
frequency matched to cases, reference dates for controls were assigned in a distribution 
matching the cases’ expected diagnosis dates.   
Blood samples were provided by 891 (91.4%) of the interviewed cases and 878 
(87.1%) of the interviewed controls. This study was approved by the Fred Hutchinson 
Cancer Research Center’s Institutional Review Board. 
 
Laboratory Methods 
 DNA was extracted from buffy coats using manual phenol chloroform method.  
Genotyping was performed at the Functional Genomics Laboratory of the Center for 
Ecogenetics and Environmental Health at the University of Washington.   
The 5’-nuclease TaqMan Detection System-based assays were developed to 
discriminate the following alleles: CYP1B1*2 (Ala119Ser), CYP1B1*3 (Leu432Val), 
COMT Val158Met and GSTP1 Ile105Val (Supplemental Table A.1).  Primers and dual-
labeled allele specific probes were designed through Assays-by-DesignSM Service-SNP 
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Genotyping by Applied Biosystems Inc. (Foster City, CA).  Each TaqMan minor groove 
binder (MGB) probe consisted of an oligonucleotide labeled both with a particular 5’ 
reporter dye and a 3’ nonfluorescent quencher.  Amplification was performed by initial 
denaturation at 95ºC for 10 minutes, followed by 40 cycles of amplification at 92ºC for 
15 seconds and annealing at 60ºC for one minute.  End-point analysis was performed on 
ABI 7900 Sequence Detection System (Applied Biosystems Inc., Foster City, CA) to 
determine the genotypes.  
The presence or absence of the glutatione-S transferase mu (GSTM1) and theta 
(GSPT1) genes was determined using a multiplex PCR (27).  Briefly, two sets of primers 
were used to amplify a 215-bp segment of the GSTM1 gene and a 480-bp segment of the 
GSTT1 gene.  Primers were also included to amplify a 268-bp segment of the ß-globin 
gene, which was used as a positive control for the PCR.  The products were separated by 
electrophoresis with ethidium bromide-stained 2.5% agarose gel (ISC BioExpress, 
Kaysville, UT) and genotyped by visual inspection using UV illumination. 
Positive controls consisting of DNA aliquots representing wild-type/wild-type, 
wild-type/mutant, mutant/mutant genotypes (characterized by DNA-sequencing) and a 
negative control (no DNA) were included in each assay performed.  Additionally, 
randomly selected samples (10%) were identified for replicate testing and were integrated 
randomly into the genotyping plates.  Laboratory staff members were blinded to case-
control status and to replicate status.    
Among the 10% of the samples for which genotypes were replicated for quality 
control assessment, the level of agreement between the samples was 100% for the COMT 
Val158Met alleles;  100% for CYP1B1*2 Ala119Ser; 94.7% for CYP1B1*3 Leu432Val; 
 8 
Estrogen Metabolizing Genes and Breast Cancer Risk  
93.2% for GSTM1*0; 96.2% for GSTP1 Ile105Val; and 96.4% for GSTT1*0.  When 
discordance occurred, the genotype was coded as a missing variable.  Additionally, the 
amount of missing data (including those removed for QC purposes) for each genotype 
was 0.0% (COMT), 2.0% (CYP1B1*2), 0.6% (CYP1B1*3), 0.5% (GSTM1), 0.2% 
(GSTP1), and 0.2% (GSTT1).   
 
Statistical Methods  
The EPT variable was categorized as never use, short-term use (< 60 months of 
use), and long-term use (≥ 60 months of use).  The ET variable was similarly categorized 
as never use, short-term use, and long-term use.  In addition, analysis examining ET use 
excluded any women who had ever used EPT due to the association observed between 
EPT use and breast cancer risk in this dataset.  
Concordance between replicate samples included for quality control purposes was 
determined for each SNP.  Testing for deviation from Hardy-Weinberg Equilibrium 
(HWE) was performed within population controls using a χ2 goodness of fit test.  Mantel-
Haenszel Chi-Square test was used for tests of associations in bivariate analyses. 
Odds Ratios (OR) and corresponding 95% CIs were calculated using unconditional 
logistic regression. ORs were adjusted for age and year of diagnosis because these were 
frequency matched variables.  The Wald’s test statistic was used to test trends in models 
containing variables with multiple levels.  We also used the Wald’s test statistic to 
determine if the trend in odds ratios associated with various genotypes differed by HT 
use. 
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In the multi-gene analysis, we considered only SNPs statistically significantly 
associated with breast cancer in the single gene analyses.  Similarly, only when a single- 
or multi-gene model was statistically significantly associated with breast cancer risk did 
we investigate the potential for a gene-hormone therapy interaction.  The exception to 
this was the investigation of interactions which have been previously reported in the 
literature. 
Interaction terms were investigated using the likelihood ratio test (LRT).  We 
estimated CYP1B1 haplotype frequencies and estimated ORs and 95% CIs associated 
with breast cancer.  Haplotype estimation was performed using Phase v.2.1.  The 
CYP1B1 haplotype with the highest frequency (G at A119S and G at L432V) served as 
the referent category. 
We accounted for multiple testing in our analyses by using the false-positive 
reporting probability (FPRP) and preset the FPRP-level criterion at 20% (based on the 
number of studies previously investigating these genes and our adequate sample size), 
and evaluated the FPRP using prior probabilities ranging from 0.1 to 0.01 (28).  
 
Results 
Demographic and hormone related characteristics of breast cancer cases and 
controls are presented in Table 1.  Similar to findings previously reported in the overall 
PACE study (26), cases had a higher BMI and were more likely to be long-term users of 
EPT than controls.  
In the single gene analyses, women homozygous for the CYP1B1*2 Ser allele 
(T/T) had a 1.69-fold increased risk of breast cancer (95% CI: 1.17-2.46) and the 
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heterozygotes (G/T) were at no increased risk (OR = 0.99 [95% CI: 0.81-1.20) compared 
to homozygous wildtypes (Table 2).  Women homozygous for the GSTP1 Val allele 
(G/G) were at 0.73 times the risk of breast cancer (95% CI: 0.54-0.99) and the 
heterozygotes (A/G) had no altered risk (OR = 1.04 [95% CI: 0.85-1.27) compared to the 
homozygous wildtype.  The COMT Met158 allele (rs4680), CYP1B1 Val432 allele 
(rs1056836), GSTM1 null allele, and GSTT1 null allele were not observed to be 
associated with risk of breast cancer.  
We investigated the possibility of reporting a false positive association between 
breast cancer and the SNPs in our study by calculating a false positive report probability 
(FPRP) for prior probabilities ranging from 0.1, 0.05, to 0.01.  We observed FPRPs equal 
to 0.11, 0.21, and 0.58, at these prior probability levels, respectively, for CYP1B1*2; and 
FPRPs equal to 0.06, 0.11, and 0.39, respectively, for GSTP1, indicating that the false-
positive reporting probability was within the 20% criterion set a priori for both of these 
SNPs at a prior probability of 0.1 but not at 0.01. 
There was no indication that the associations seen for the homozygous variant 
allele of CYP1B1*2 differed according to the use of EPT or ET (Table 3). For GSTP1, the 
reduced risk of breast cancer among women homozygous for the Val allele was limited to 
never users of ET (p-value for interaction= 0.004). While we had data on duration and 
recency of use, our sample size was too limited to investigate gene-disease associations 
stratified by EPT duration and recency. 
The two genes found to have associations with breast cancer, CYP1B1*2 and 
GSTP1, were assessed for a possible gene-gene interaction.  However, we observed no 
evidence of this (p-value = 0.36; Table 4).  We also observed no elevation in risk 
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associated with the CYP1B1*2-*3 haplotypes (compared to GG, OR = 1.0 [95% CI: 0.8-
1.1] for GC; OR = 1.0 [95% CI: 0.8-1.3] for TG; OR = 1.1 [95% CI: 0.9-1.3] for TC; data 
not shown).    
Additionally, we investigated possible interactions between genes previously 
reported in the literature (19-21,23-25) but did not detect any among the following 
combined gene variables: GSTT1-GSTM1, COMT-GSTP1, COMT-GSTT1, COMT-
GSTM1, COMT-GSTM1-GSTT1, and GSTP1-GSTM1-GSTT1 (Supplemental Table 1).   
We also investigated a possible EPT interaction with combined genes as reported 
by Mitrunen, et al, and did not observe evidence that the risk of breast cancer associated 
with combined genes varied according to EPT use within the COMT-GSTP1 combined 
variable (p-value = 0.19; Supplemental Table 2).  With the COMT-GSTT1 and COMT-
GSTM1 combined variables, while we observed a greater risk in short-term users of EPT 
than was predicted by their separate associations  (p-value = 0.004 and 0.001, 
respectively), the pattern of risk when stratified by EPT was not what we would have 
expected a priori (comparing two to zero high risk genotypes in COMT-GSTT1, OR =  
0.8 [95% CI: 0.5-1.4] for never users, OR = 24.4 [95% CI: 3.0-200.2] for EPT use < 30 
months, OR =0.8 [95% CI: 0.3-2.4] for EPT use of 30+ months; in COMT-GSTM1, OR =  
0.7 [95% CI: 0.4-1.1] for never users, OR = 8.5 [95% CI: 1.4-52.4] for EPT use < 30 
months, and OR =1.3 [95% CI: 0.7-2.3] for EPT use of 30+ months), admittedly with a 
constrained sample size for this analysis.  
Our results were unchanged when limited to White women for all of the analyses 
presented above.   
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Discussion 
Our study observed that variants in the CYP1B1 and GSTP1 genes were 
associated with breast cancer risk.  In interpreting these results, we must first consider the 
potential limitations of our study.  Lab errors resulting in non-differential 
misclassification of genotypes could bias ORs toward the null.  However, QC analyses 
indicated high correlations between replicate samples.  Also, allele distributions were 
consistent with HWE, and there was a minimal amount of missing genotype data. 
Another potential limitation was the omission of a portion of the interviewed 
cases (8.6%) and controls (12.9%) who were otherwise eligible for the parent study but 
did not donate a blood specimen. Comparison of the women who donated blood with all 
participants interviewed is reassuring in that there were no discernible differences in risk 
factor distributions and risk estimates, nor did the cases who donated blood vary from the 
entire case series in terms of stage and other disease features. Another possible source of 
selection bias, however, could arise from the 19.4% of cases and 26.2% of controls who 
were identified by CSS but did not participate in the parent study. For analyses that 
consider interview data, the ability of women to recall past exposures is a potential 
concern. Specific tools designed to assist recall were employed in this study, including a 
lifetime calendar and colored photographs of medications. As a check on the quality of 
recall in PACE participants, we previously compared self-reported data on several 
categories of medications with pharmacy records and found overall agreement to be quite 
good (29). 
A large number of individual studies have reported on associations between genes 
in this pathway and breast cancer risk (11-13,15,18,20-25,30-36).  However, no genome-
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wide association studies have reported findings for regions encompassing these genes 
(37,38). In addition to several large individual studies, a meta-analysis of  CYP1B1*2 
found no association between breast cancer risk and the Ala/Ser genotype (OR = 1.1 
[95% CI: 0.9-1.2]), or the Ser/Ser genotype (OR = 1.0 [95% CI: 0.8-1.2]) 
(9,11,13,15,31,33).  Findings from haplotype analyses have not been any more 
compelling.  Among three large studies investigating the risk of breast cancer associated 
with haplotypes in the CYP1B1 gene, one observed a 1.5-fold increased risk comparing 
women homozygous for G,T,C at positions 48, 119, and 432, respectively, to those with 
the most common haplotype (95% CI: 1.0-2.1; p-value = 0.03), and two others reported 
no alteration in breast cancer risk in any CYP1B1 haplotype (15,31,33).  The generally 
negative findings from prior studies argue that the 1.7-fold increased risk of breast cancer 
that we observed among women with the CYP1B1*2 Ser allele should be interpreted with 
caution.  
For GSTP1, a pooled analysis of 301 cases and 397 controls, reported that the 
G/G genotype (Val homozygotes) was associated with an increased risk of breast cancer 
(OR = 1.86 [95% CI: 1.05-3.3]) (14), but two larger studies have observed either a 
decreased risk (OR = 0.6 [95% CI: 0.3-1.0]) or no association among the Val 
homozygotes (OR = 0.9 [95% CI: 0.5-1.4]) (19,20).  However, among post-menopausal 
women these studies have observed borderline decreased risks associated with Val 
homozygotes compared to wildtype homozygotes (OR = 0.5 [95% CI: 0.2-1.1], and OR = 
0.7 [95% CI: 0.4-1.1] (19,20).  In the two studies that stratified by use of HT, one 
reported a greater reduction in breast cancer risk observed among ever users of ET (OR = 
0.2 [95% CI: 0.04-0.8]) than never users (OR = 0.6 [95% CI: 0.2-2.0]).(20)  But another 
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study observed no differential association with Val homozygosity according to use of 
EPT (OR = 0.8 [95% CI: 0.5-1.2] for never users; OR = 0.8 [95% CI: 0.4-1.5] for ever 
users) (20).   
Our study, the largest to date examining the association between GSTP1 and 
breast cancer risk, observed women with the GSTP1 Val/Val genotype generally to be at 
a reduced risk of breast cancer, and is in broad agreement with the findings of other 
epidemiologic studies reported for post-menopausal women.  We evaluated the 
probability that this finding represented a false-positive association and calculated the 
likelihood of that to be 11% at a prior probability of 0.05 (at lower prior probabilites, the 
false-reporting probability is higher).  Thus, if the prior probability of an association 
between the GSTP1 Val/Val allele is at least 5% (given the a priori biological rationale 
for investigating SNPs within this gene, it is reasonable to assume the prior probability is 
5% or greater) the probability of this finding being a false-positive association is 
relatively small. 
Additionally, while it is plausible that the reduction in breast cancer risk 
associated with the GSTP1 Val/Val genotype is most pronounced in never users of ET, 
these findings would need to be replicated before any inferences can be made. Adding 
complexity to the issue are the conflicting findings demonstrating varying levels of 
catalytic activity between the variant protein and the wildtype protein.  Some 
demonstrated a higher Vmax for the Val105 isoform, while others showed a lower 
catalytic efficiency for the Val105 isoform compared to wildtype (39-42). 
Our null findings with COMT, GSTM1, and GSTT1 and breast cancer are in broad 
agreement with previous reports from pooled and meta-analyses (9,14,22).  Also, if 
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account is taken of the effect modification by age in the HuGE review of CYP1B1*3 (for 
Val/Leu compared to Leu/Leu genotypes in Caucasians women over 60 years of age: OR 
= 1.1 [95% CI: 0.8-1.4]; 51-54 year olds: OR = 2.5 [95% CI: 1.1-5.7]; 55-59 year olds: 
OR = 1.9 [95% CI: 1.1-3.6]) (43),  then our findings in this study of women aged 65 and 
older are consistent with prior works as well.   
Previous studies have also investigated possible gene-gene combinations within 
this set of genes as there is strong biologic rationale for considering the joint effects of 
genes within this shared pathway, with several studies (18,20,23-25,44) but not all (21), 
reporting associations between high risk genotypes from combined genes in this pathway 
and breast cancer risk.  However, with the exception of two studies reporting marginally 
significant increased risks of breast cancer associated with combined GSTP1, GSTM1, 
and GSTT1, no specific gene-gene combination has been observed in more than one study 
(18,20,23-25,44).  We investigated but did not detect any gene-gene interactions within 
the catechol estrogen pathway.  
A previous study reported on a potential interaction between combined gene 
variables and EPT in breast cancer (24).  Specifically, among EPT users of greater than 
30 months, Mitrunen, et al observed the risk of breast cancer to be heightened in relation 
to COMT-GSTM1 (OR = 9.1 [95% CI: 1.8-45.0]), COMT-GSTT1 (OR = 8.4 [95% CI: 
1.4-49.0]), and COMT-GSTP1 (OR = 7.0 [95% CI: 1.2-40.6] comparing 2 to 0 high risk 
genotypes).  An increased risk was not similarly observed among EPT users of less than 
30 months (COMT-GSTM1: OR = 0.7 [95% CI: 0.2-3.5] comparing 2 to 0 high risk 
genotypes); COMT-GSTT1: OR = 1.7 [95% CI: 0.3-10.5]), and COMT-GSTP1 (OR = 2.3 
[95% CI: 0.4-14.1]).  While we observed a greater risk associated with two high risk 
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genotypes for short-term users of EPT for both the COMT-GSTT1 combined variable and 
the COMT-GSTM1 combined variable, these patterns of risk were not what we had 
hypothesized a priori (nor were the patterns in agreement with those reported by 
Mitrunen, et al), and thus, we cannot draw any conclusions based on these findings. 
Our study observed a 27% reduction in breast cancer risk associated with the 
GSTP1 Val/Val genotype.  However, we are the first study to report a statistically 
significant decreased risk among post-menopausal women; clearly, replication of our 
results is needed before any firm conclusion can be drawn.  Based on this study and the 
existing epidemiologic literature, there is little evidence that any SNPs in the catechol 
estrogen metabolism pathway, with the exception of GSTP1, have a main effect on breast 
cancer risk and there is little evidence supporting interactions between any of these genes 
and HT use. 
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Table 1.  Characteristics of breast cancer cases and controls  
 
Characteristic  Case 
n (%)1,2 
Control 
n (%)1,2 
  n=891 n=878 
Age at reference date (yrs) 65-69 278 (31.2) 278 (31.7) 
 70-74 613 (68.8) 600 (68.3) 
   
Age at menopause (yrs)3 < 39 74 (9.6) 98 (11.2) 
 40-44 115 (14.9) 130 (14.8) 
 45-49 233 (30.1) 229 (26.1) 
 50-54 257 (33.2) 239 (27.2) 
 ≥ 55 95 (12.3) 103 (11.7) 
 Missing data 117 79 
   
Age at First FTP (yrs) < 30 720 (81.1) 726 (82.8) 
 ≥ 30 168 (18.9) 151 (17.2) 
 Missing data 3 1 
   
Cause of menopause Natural menopause 508 (57.9) 519 (59.9) 
 Induced menopause 122 (13.9) 124 (14.3) 
 Simple Hysterectomy  207 (23.6) 198 (22.8) 
 Other 41 (4.7) 26 (3.0) 
 Missing data 13 11 
   
BMI quartiles 16.00-22.96 169 (19.5) 211 (24.8) 
 22.97- 26.01 221 (25.6) 213 (25.1) 
 26.02-30.11 244 (28.2) 211 (24.8) 
 30.12- 48.70 231 (26.7) 214 (25.2) 
 Missing data 26 29 
   
Mean BMI  27.5 (5.7) 26.9 (5.4) 
   
EPT Never use 648 (73.0) 697 (79.8) 
 < 60 months of use. 80 (9.0) 80 (9.2) 
 ≥ 60 months of use 160 (18.0) 96 (11.0) 
 Missing data 3 5 
   
ET Never use 407 (46.1) 412 (47.2) 
 < 60 months of use. 157 (17.8) 176 (20.2) 
 ≥ 60 months of use 319 (36.1) 284 (32.6) 
 Missing data 8 6 
   
Race Caucasian 854 (95.9) 814 (92.7) 
 African American 11 (1.2) 27 (3.1) 
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 Asian 17 (1.9) 21 (2.4) 
 Other/unknown 9  (1.0) 16 (1.8) 
 
 
 
FTP: Full term pregnancy; BMI: Body Mass Index 
 
1. with the exception of mean BMI: mean (standard deviation) 
2. Some percentages do not sum to 100% due to rounding 
3. Using data imputed from hormone therapy use and bilateral oophorectomy status 
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Table 2. The risk of breast cancer associated with genetic variation as investigated in 
single gene models 
1. Adjusted for age and year of diagnosis (reference date for controls)  
Gene Genotype Case 
n (%) 
Control 
n (%) 
OR1 95% CI 
       
COMT G/G (Val/Val) 224 (25.1) 211 (24.0) 1.0 (ref)   
 G/A (Val/Met) 427 (48.0) 431 (49.1) 0.94 0.74 1.18 
 A/A (Met/Met) 240 (26.9) 236 (26.9) 0.97 0.75 1.26 
     
CYP1B1*2 G/G (Ala/Ala) 452 (51.5) 454 (53.0) 1.0 (ref)   
 G/T (Ala/Ser) 341 (38.8) 353 (41.2) 0.99 0.81 1.20 
 T/T  (Ser/Ser) 84 (9.6) 50 (5.8) 1.69 1.17 2.46 
     
CYP1B1*3 C/C (Leu/Leu) 289 (32.6) 271 (31.0) 1.0 (ref)   
 C/G (Leu/Val) 409 (46.2) 427 (48.9) 0.90 0.73 1.11 
 G/G (Val/Val) 188 (21.2) 176 (20.1) 1.00 0.77 1.30 
     
GSTP1 A/A (Ile/Ile) 382 (42.9) 366 (41.8) 1.0 (ref)   
 A/G (Ile/Val)  417 (46.8) 390 (44.6) 1.04 0.85 1.27 
 G/G (Val/Val) 92 (10.3) 119 (13.6) 0.73 0.54 0.99 
     
GSTM1 Present 421 (47.4) 415 (47.4) 1.0 (ref)   
 Null  467 (52.5) 460 (52.6) 1.00 0.83 1.21 
     
GSTT1 Present 744 (83.5) 738 (84.2) 1.0 (ref)   
 Null 147 (16.5) 139 (15.8) 1.04 0.81 1.34 
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Table 3. The risk of breast cancer associated with CYP1B1*2 and GSTP1 Ile105Val  
stratified by EPT and ET use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Case1 Control1 OR2 95% CI p-value3 
      
CYP1B1       
 Never EPT Users     
G/G 317 (49.5) 346 (51.0) 1.0 (ref)    
G/T 259 (40.5) 291 (42.9) 0.98 0.78 1.23  
T/T 64 (6.9) 42 (6.2) 1.63 1.07 2.48 0.14 
 Ever EPT Users     
G/G 133 (56.8) 105 (60.7) 1.0 (ref)    
G/T 81 (34.6) 60 (34.7) 1.07 0.70 1.62  
T/T 20 (8.6) 8 (4.6) 1.90 0.80 4.51 0.001 
    pint = 0.96  
 Never ET Users    
G/G 134 (49.3) 155 (50.2) 1.0 (ref)    
G/T 113 (41.5) 137 (44.3) 0.98 0.70 1.38  
T/T 25 (9.2) 17 (5.5) 1.69 0.87 3.27 0.91 
 Ever ET Users4      
G/G 179 (49.3) 191 (51.6) 1.0 (ref)    
G/T 145 (39.9) 154 (41.6) 1.01 0.74 1.38  
T/T 39 (10.7) 25 (6.8) 1.57 0.91 2.72 0.23 
   pint = 0.64  
 missing    
 14 (1.6) 21 (2.4)     
       
GSTP1      
 Never EPT Users   
A/A 284 (43.8) 284 (40.8) 1.0 (ref)    
A/G 293 (45.2) 315 (45.2) 0.94 0.75 1.18  
G/G 71 (11.0) 95 (13.6) 0.73 0.51 1.03 0.11 
 Ever EPT Users   
A/A 97 (40.4) 80 (45.4) 1.0 (ref)    
A/G 122 (50.8) 72 (40.9) 1.40 0.92 2.11  
G/G 21 (8.8) 24 (13.6) 0.73 0.38 1.41 0.97 
   pint = 0.41  
 Never ET Users   
A/A 125 (45.3) 103 (32.8) 1.0 (ref)    
A/G 125 (45.3) 166 (52.9) 0.63 0.44 0.90  
G/G 26 (9.4) 45 (14.3) 0.45 0.26 0.78 0.001 
 Ever ET Users4   
A/A 55 (59.8) 37 (40.2) 1.0 (ref)    
A/G 77 (75.5) 25 (24.5) 1.30 0.96 1.78  
G/G 12 (46.2) 14 (53.8) 0.97 0.61 1.54 0.53 
   pint = 0.004  
 missing    
 0 (0.0) 3 (0.3)    
1. Some percentages do not sum to 100% due to rounding  
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2. Adjusted for age and year of diagnosis (reference date for controls). 
3. p-value for test of trend 
4. Limited to exclusive users of ET 
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Table 4.  The risk of breast cancer associated with genetic variation modeled as 
CYP1B1*2- GSTP1gene-gene interactions 
 
 
 
 
 
 
 
 
 
 
Case 
n (%)1 
Control 
n (%)1 
# High Risk 
Genotypes2 
OR3 95% CI 
     
 GSTP1 CYP1B1*2    
79 (9.0) 108 (12.6) 0  0 1.0 (ref)   
10 (1.1) 8 (0.9) 0 1 1.81 0.64 5.07 
714 (81.4) 696 (81.5) 1 0 1.53 0.99 2.35 
74 (8.4) 42 (4.9) 1 1 2.78 1.46 5.32 
    pint = 0.36 
 
1. Some percentages do not sum to 100% due to rounding  
2. High risk genotypes as determined in the single gene analyses: A/A and A/G for 
GSTP1 and T/T for CYP1B1.   
3. Adjusted for age and year of diagnosis (reference date for controls) 
 
 
